A new study compared MRI-targeted biopsy to systematic biopsy for prostate cancer screening. The study found that MRI-targeted biopsy reduced overdiagnosis of low-grade cancer by more than half, leading to fewer unnecessary biopsies and diagnoses of insignificant disease. However, there was a slight delay in diagnosing higher-risk disease with the MRI-targeted approach. The results suggest that guidelines should be updated to favor MRI-targeted biopsy over systematic biopsy. While more data may be needed before changing screening protocols, the study provides evidence that MRI-targeted biopsy may be a more cost-effective and beneficial approach to prostate cancer screening.
Source link
Which Biopsy for Elevated PSA?
